Nucleic Acids Research, 2000, Vol. 28, No. 14 2717-2725
© 2000 Oxford University Press
Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation
Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, PO Box 9503, 2300 RA Leiden, The Netherlands and 1Department of Medicinal Chemistry, Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
Several studies have shown improved efficacy of cholesteryl-conjugated phosphorothioate antisense oligodeoxynucleotides. To gain insight into the mechanisms of the improved efficacy in vivo, we investigated the disposition of ISIS-9388, the 3'-cholesterol analog of the ICAM-1-specific phosphorothioate oligodeoxynucleotide ISIS-3082, in rats. Intravenously injected [3H]ISIS-9388 was cleared from the circulation with a half-life of 49.9 ± 2.2 min (ISIS-3082, 23.3 ± 3.8 min). At 3 h after injection, the liver contained 63.7 ± 3.3% of the dose. Compared to ISIS-3082, the hepatic uptake of ISIS-9388 is ~2-fold higher. Endothelial, Kupffer and parenchymal cells accounted for 45.7 ± 5.7, 33.0 ± 5.9 and 21.3 ± 2.6% of the liver uptake of [3H]ISIS-9388, respectively, and intracellular concentrations of ~2, 75 and 50 µM, respectively, could be reached in these cells (1 mg/kg dose). Preinjection with polyinosinic acid or polyadenylic acid reduced the hepatic uptake of [3H]ISIS-9388, which suggests the involvement of (multiple) scavenger receptors. Size exclusion chromatography of mixtures of the oligonucleotides and rat plasma indicated that ISIS-9388 binds to a larger extent to high molecular weight proteins than ISIS-3082. Analysis by agarose gel electrophoresis indicated that ISIS-9388 binds more tightly to plasma proteins than ISIS-3082. The different interaction of the oligonucleotides with plasma proteins possibly explains their different dispositions. We conclude that cholesterol conjugation results in high accumulation of phosphorothioate oligodeoxynucleotides in various liver cell types, which is likely to be beneficial for antisense therapy of liver-associated diseases.
* To whom correspondence should be addressed. Tel: +31 71 527 6038; Fax: +31 71 527 6032; Email: bijsterb@chem.leidenuniv.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Cheng, Z. Ye, R. V. Guntaka, and R. I. Mahato Enhanced Hepatic Uptake and Bioactivity of Type {alpha}1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 797 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Bijsterbosch, M. Manoharan, R. Dorland, R. van Veghel, E. A. L. Biessen, and T. J. C. van Berkel bis-Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Are Highly Selectively Taken Up by the Liver J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Bijsterbosch, C. Ying, R. L. A. de Vrueh, E. de Clercq, E. A. L. Biessen, J. Neyts, and T. J. C. van Berkel Carrier-Mediated Delivery Improves the Efficacy of 9-(2-Phosphonylmethoxyethyl)Adenine against Hepatitis B Virus Mol. Pharmacol., September 1, 2001; 60(3): 521 - 527. [Abstract] [Full Text] [PDF]
|
|